EyeBio is a company developing a new generation of therapies to protect, restore, and improve vision.

EyeBio

Cloudflare Hosting

Person Schema

Google

Google Cloud

Risk, Safety, Compliance

Sandra Herder

Executive Assistant to Chief Operating Officer

Laura Fougman

Chief Regulatory Officer

Loni RAC

Srinivas Akkaraju

Anthony P. Adamis

Kate Bingham

Michael Ross

Andreas Wallnöfer

David Guyer

Co-Founder and CEO

Co-Founder

Greater New York Area Acquired Companies With Fewer Than 100 Employees

City of New York Companies With More Than $1M in Revenue (Top 10K)

Northeastern US Acquired Companies With Fewer Than 100 Employees

Companies With Fewer Than 100 Employees (Top 10K)

Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Series A - Eyebiotech

Jeito Capital

Samsara BioCapital

SV Health Investors

Seed Round - Eyebiotech

New York

United States

North America

Eyebiotech

Startup M&A Trends Higher As PE Leads, But Remains Sluggish Compared To Earlier Years

Midyear Forecast: Top Trends To Watch In H2 2024 — From Chips To AI Funds

North American Startup Funding Jumped Higher In Q2

Crunchbase Monthly Recap May 2024: AI Leads Alongside An Uptick In Billion-Dollar Rounds

Merck’s Acquisition of Eyebiotech

Merck could pay up to $3 billion to boost its retinal disease candidate pipeline

Jeito Capital to sell EyeBiotech to Merck & Co for $3bn

Merck Reaches $1.3 Billion Deal for Eye-Drug Company EyeBio - WSJ

Merck to Acquire EyeBio

Puerto Rico

Russian Federation

Europe

India

Asia

United Kingdom

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Nov 21, 2024 8:04 AM	8c0c6fff
public peers	general	Jul 24, 2024 3:21 PM	11613537
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 28, 2024 1:51 PM	e252b21f
crunchbase profile	general	Oct 29, 2024 9:03 AM	7f24c52f
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	f82665f3
peers	general	Jul 24, 2024 3:21 PM	b117f610
news basic	general	Jul 24, 2024 3:21 PM	a51e6e9a
bundesanzeiger	filings
financials download nd	financials
private financials	financials

EYEB

COM:EYEBIOTECH

EyeBio